Category Archives: Immunology

Immunology

Prescient Intelligence & Insight Announces Recent Appointments to the Senior Team – BioSpace

LONDON, Jan. 29, 2020 /PRNewswire/ --Prescient, a biopharma product and portfolio strategy partner, announces the recent appointment of three new senior members to its Intelligence & Insight business: Jeanne Penn, Ben Kebble and Dr. Mladen Tomich. They join the existing Intelligence & Insight team, shaping the competitive strategy of Prescient's clients through enhanced decision support.

Jeanne Penn joins Prescient after spending more than 25 years providing strategic insight and planning support to the biopharmaceutical industry. Since completing her MSc, Jeanne has held leadership roles at various companies, including EMD Serono and Genzyme. She brings a depth of biopharma experience in brand and strategic planning, indication prioritization, competitive intelligence, workshop design and facilitation and integration of multiple external perspectives to inform decision making. At Prescient, Jeanne will leverage her expertise in rare diseases, multiple sclerosis, immunology, inflammatory diseases and fertility to grow and develop client relationships and lead client engagements.

Ben Kebble joins Prescient after spending more than 15 years at Genzyme, MedImmune/AstraZeneca, Cancer Research UK and several biotech companies, where his responsibilities have included leading a global competitive intelligence function, running drug discovery projects, alliance management and business development. Ben has completed a BSc in animal biology, an MBA and postgraduate courses in project management. At Prescient, Ben will leverage his expertise in oncology and his broader experience in respiratory disease, immunological and infectious diseases and emerging therapeutic technologies to lead multiple client engagements in both the R&D and commercial settings.

Dr. Mladen Tomich joins Prescient after spending more than 10 years in drug discovery, real-world data analysis and pharmaceutical market intelligence. Since completing his PhD in microbiology, Mladen has held research and commercial roles at various companies, including Merck & Co. and MedImmune/AstraZeneca, where he led projects focused on the discovery of novel anti-infectives for the treatment and prevention of serious bacterial infections. He brings a depth of functional and therapeutic experience and will lead client engagements in immunology, infectious diseases, vaccines and rare diseases.

"Our clients need a specialist partner who has the disease area, functional and market expertise required to develop business-relevant, actionable and impactful insight from data and intelligence," said Dr. Rakesh Verma, Prescient's EMEA and APAC President. "Jeanne, Ben and Mladen bring the deep subject matter expertise and industry knowledge that is critical to our clients' businesses."

Biographies and contact information for the Prescient Intelligence & Insight team can be found on http://www.PrescientHG.com.

About Prescient

At Prescient, science is at the core of everything we do. We are a biopharma product and portfolio strategy partner that specializes in turning the science of molecules into optimal patient outcomes and client value. Across therapeutic areas, we help develop winning strategies. When companies partner with us, a molecule in their hands has greater potential for success than the same science in the hands of their competitors.

Prescient Intelligence & Insight, a Prescient Healthcare Group business, offers best-in-class biopharmaceutical intelligence by providing impactful insight and decision support to product and portfolio teams from early clinical development through to loss of exclusivity.

Prescient has been a portfolio company of Baird Capital since 2017. For more information, please visit: http://www.PrescientHG.com.

Contact:Christina Maffei+1 908 342 3556232815@email4pr.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/prescient-intelligence--insight-announces-recent-appointments-to-the-senior-team-300994810.html

SOURCE Prescient Healthcare Group

See the article here:
Prescient Intelligence & Insight Announces Recent Appointments to the Senior Team - BioSpace

Immunology

Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in…

INDIANAPOLIS, Jan. 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD5, an investigational Phase 3, randomized, placebo-controlled study evaluating the safety and efficacy of baricitinib for the treatment of adult patients with moderate to severe atopic dermatitis (AD). The primary endpoint was defined by the proportion of patients achieving at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) at Week 16.

"Today's results, together with the previously reported positive top-line results from our Phase 3 trials, reinforce our commitment to pursue the first oral JAK inhibitor treatment in the U.S. for individuals living with the chronic and often relapsing skin condition that is AD," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly.

BREEZE-AD5 is a multicenter, double-blind, randomized, placebo-controlled study designed for and conducted in North America, evaluating the efficacy and safety of the 1-mg and 2-mg doses of baricitinib monotherapy for the treatment of adult patients with moderate to severe AD. In this study, the 2-mg dose of baricitinib met the primary endpoint as defined by the proportion of participants achieving EASI75 at Week 16, and key secondary endpoints including another measure of skin inflammation defined by clear or almost clear skin and at least 2 points improvement on the validated Investigator's Global Assessment for AD (vIGA 0 or 1 at Week 16), and reduced itch severity.

Placebo (n=147)

Baricitinib 1-mg (n=147)

Baricitinib 2-mg (n=146)

EASI75 at Week 16, n (%)

12 (8.2)

19 (12.9)

43 (29.5)***

vIGAa of 0 or 1 at Week 16, n (%)

8 (5.4)

19 (12.9)*

35 (24.0)***

4-point improvement in Itch NRS atWeek 16, n (%)

7 (5.7)

21 (15.9)*

33 (25.2)***

P n.s. * P 0.05, and *** P0.001 for baricitinib compared to placebo by analysis unadjusted for multiplicity. Non-responder imputation upon rescue with Topical corticosteroid (TCS).

avIGA = validated Investigator's Global Assessment.

The safety profile in BREEZE-AD5 was consistent with the known safety findings of baricitinib in AD. The most common treatment-emergent adverse events (TEAEs) included upper respiratory tract infections, nasopharyngitis, and diarrhea. No venous thromboembolic events (VTEs) or deaths were reported in the trial.

"The results show the potential that baricitinib could offer as an additional treatment option to patients where there are otherwise limited choices," said Eric Simpson, MD, MCR, Professor of Dermatology and Director of Clinical Research at Oregon Health & Science University in Portland, and global Principal Investigator for the BREEZE-AD5 clinical development program.

Lilly recently submitted baricitinib for regulatory review in Europe as a treatment for patients with moderate to severe AD and plans to submit for approval in the U.S. and Japan in 2020. The full results from the BREEZE-AD5 study will be disclosed at future scientific venues and in peer-reviewed journals.

Baricitinib is approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) in more than 60 countries, including the U.S., member states of the EU and Japan, and is marketed as OLUMIANT.

Indication and Usage for OLUMIANT (baricitinib) tablets (in the United States) for RA patientsOLUMIANT (baricitinib) 2-mg is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Limitation of Use: Use of OLUMIANT in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

IMPORTANT SAFETY INFORMATION FOR OLUMIANT (baricitinib) TABLETS

WARNING: SERIOUS INFECTIONS, MALIGNANCY, AND THROMBOSIS

SERIOUS INFECTIONS: Patients treated with Olumiant are at risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt Olumiant until the infection is controlled. Reported infections include:

Carefully consider the risks and benefits of Olumiant prior to initiating therapy in patients with chronic or recurrent infection.

Closely monitor patients for the development of signs and symptoms of infection during and after treatment with Olumiant including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

MALIGNANCIES: Lymphoma and other malignancies have been observed in patients treated with Olumiant.

THROMBOSIS: Thrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), has been observed at an increased incidence in patients treated with Olumiant compared to placebo. In addition, there were cases of arterial thrombosis. Many of these adverse events were serious and some resulted in death. Patients with symptoms of thrombosis should be promptly evaluated.

WARNINGS AND PRECAUTIONS

SERIOUS INFECTIONS: The most common serious infections reported with Olumiant included pneumonia, herpes zoster and urinary tract infection. Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus and BK virus were reported with Olumiant. Some patients have presented with disseminated rather than local disease and were often taking concomitant immunosuppressants such as methotrexate or corticosteroids. Avoid Olumiant in patients with an active, serious infection, including localized infections. Consider the risks and benefits of treatment prior to initiating Olumiant in patients:

Closely monitor patients for infections during and after Olumiant treatment. Interrupt Olumiant if a patient develops a serious infection, an opportunistic infection, or sepsis. Do not resume Olumiant until the infection is controlled.

Tuberculosis Before initiating Olumiant evaluate and test patients for latent or active infection and treat patients with latent TB with standard antimycobacterial therapy. Olumiant should not be given to patients with active TB. Consider anti-TB therapy prior to initiating Olumiant in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection. Monitor patients for TB during Olumiant treatment.

Viral Reactivation Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical studies with Olumiant. If a patient develops herpes zoster, interrupt Olumiant treatment until the episode resolves.

The impact of Olumiant on chronic viral hepatitis reactivation is unknown. Screen for viral hepatitis in accordance with clinical guidelines before initiating Olumiant.

MALIGNANCY AND LYMPHOPROLIFERATIVE DISORDERS: Malignancies were observed in Olumiant clinical studies. Consider the risks and benefits of Olumiant prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing Olumiant in patients who develop a malignancy. NMSCs were reported in patients treated with Olumiant. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.

THROMBOSIS: Thrombosis, including DVT and PE, has been observed at an increased incidence in Olumiant-treated patients compared to placebo. In addition, arterial thrombosis events in the extremities have been reported in clinical studies with Olumiant. Many of these adverse events were serious and some resulted in death. There was no clear relationship between platelet count elevations and thrombotic events. Use Olumiant with caution in patients who may be at increased risk of thrombosis. If clinical features of DVT/PE or arterial thrombosis occur, evaluate patients promptly and treat appropriately.

GASTROINTESTINAL PERFORATIONS: Gastrointestinal perforations have been reported in Olumiant clinical studies, although the role of JAK inhibition in these events is not known. Use Olumiant with caution in patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis). Promptly evaluate patients who present with new onset abdominal symptoms for early identification of gastrointestinal perforation.

LABORATORY ABNORMALITIES:Neutropenia Olumiant treatment was associated with an increased incidence of neutropenia (absolute neutrophil count [ANC] <1000 cells/mm3) compared to placebo. Avoid initiation or interrupt Olumiant treatment in patients with an ANC <1000 cells/mm3. Evaluate at baseline and thereafter according to routine patient management.

Lymphopenia Absolute lymphocyte count (ALC) <500 cells/mm3 were reported in Olumiant clinical trials. Lymphocyte counts less than the lower limit of normal were associated with infection in patients treated with Olumiant, but not placebo. Avoid initiation or interrupt Olumiant treatment in patients with an ALC <500 cells/mm3. Evaluate at baseline and thereafter according to routine patient management.

Anemia Decreases in hemoglobin levels to <8 g/dL were reported in Olumiant clinical trials. Avoid initiation or interrupt Olumiant treatment in patients with hemoglobin <8 g/dL. Evaluate at baseline and thereafter according to routine patient management.

Liver Enzyme Elevations Olumiant treatment was associated with increased incidence of liver enzyme elevation compared to placebo. Increases to 5x and 10x upper limit of normal were observed for both ALT and AST in patients in Olumiant clinical trials.

Evaluate at baseline and thereafter according to routine patient management. Promptly investigate the cause of liver enzyme elevation to identify potential cases of drug-induced liver injury. If increases in ALT or AST are observed and drug-induced liver injury is suspected, interrupt Olumiant until this diagnosis is excluded.

Lipid Elevations Treatment with Olumiant was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol. Assess lipid parameters approximately 12 weeks following Olumiant initiation. Manage patients according to clinical guidelines for the management of hyperlipidemia.

VACCINATIONS: Avoid use of live vaccines with Olumiant. Update immunizations in agreement with current immunization guidelines prior to initiating Olumiant therapy.

ADVERSE REACTIONSAdverse reactions (1%) include: upper respiratory tract infections (16.3%, 14.7%, 11.7%), nausea (2.7%, 2.8%, 1.6%), herpes simplex (0.8%, 1.8%, 0.7%) and herpes zoster (1.0%, 1.4%, 0.4%) for Olumiant 2 mg, baricitinib 4 mg, and placebo, respectively.

USE IN SPECIFIC POPULATIONSPREGNANCY AND LACTATION: No information is available to support the use of Olumiant in pregnancy or lactation. Advise women not to breastfeed during treatment with Olumiant.HEPATIC AND RENAL IMPAIRMENT: Olumiant is not recommended in patients with severe hepatic impairment or in patients with severe renal impairment.

Please click to access full Prescribing Information, including Boxed Warning about Serious infections, Malignancies, and Thrombosis, and Medication Guide.

BA HCP ISI 11OCT2019

About BREEZE-AD5BREEZE-AD5, a multicenter, double-blind, randomized, placebo-controlled, Phase 3 study in adult patients with moderate to severe atopic dermatitis (AD). BREEZE-AD5, designed for and conducted in North America, evaluated the efficacy and safety of the 1-mg and 2-mg doses of baricitinib monotherapy for the treatment of adult patients with moderate to severe AD. The primary endpoint was defined by the proportion of participants achieving Eczema Area and Severity Index 75 (EASI75) at Week 16. BREEZE-AD5 completes the read out from the BREEZE development program, following the recent topline results from BREEZE-AD4. BREEZE-AD1, -AD2 and -AD7 results were disclosed in 2019.

About OLUMIANTOLUMIANT is a once-daily, oral JAK inhibitor approved in the U.S. for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF inhibitor therapies, and approved outside of the U.S. for patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more DMARDs.1 There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases.2 OLUMIANT has greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3; however, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.1 OLUMIANT is approved in more than 60 countries.

About Atopic DermatitisAtopic dermatitis (AD), or atopic eczema, is a chronic, relapsing skin disease characterized by intense itching, dry skin and inflammation that can be present on any part of the body.3 AD is a heterogeneous disease both clinically and biologically, but may be characterized by chronic baseline symptoms of itch, redness and skin damage that are often punctuated with episodic, sometimes unpredictable, flares or exacerbations.4,5 AD affects approximately 1-3% of adults worldwide.6

Moderate to severe AD is characterized by intense itching, resulting in visibly damaged skin.7 Like other chronic inflammatory diseases, AD is immune-mediated and involves a complex interplay of immune cells and inflammatory cytokines.8

About Lilly in DermatologyBy following the science through unchartered territory, we continue Lilly's legacy of delivering innovative medicines that address unmet needs and have significant impacts on people's lives around the world. Skin-related diseases are more than skin deep. We understand the devastating impact this can have on people's lives. At Lilly, we are relentlessly pursuing a robust dermatology pipeline to provide innovative, patient-centered solutions so patients with skin-related diseases can aspire to live life without limitations.

About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at http://www.lilly.com and newsroom.lilly.com/social-channels. P-LLY

About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

This press release also contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about OLUMIANT (baricitinib) as a treatment for patients with rheumatoid arthritis and as a potential treatment for patients with moderate- to severe atopic dermatitis, and reflects Lilly's and Incyte's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that OLUMIANT will receive additional regulatory approvals or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's and Incyte's most recent respective Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly and Incyte undertake no duty to update forward-looking statements to reflect events after the date of this release.

1 Olumiant Prescribing Information, 2019.2 Walker JG and Smith MD. J Rheumatol. 2005;32;1650-1653.3 Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. The Journal of Allergy and Clinical Immunology. 2006;118: 226-32.4 Thijs JL, Strickland I, Bruijnzeel-Koomen C, et. al. Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis. The Journal of Allergy and Clinical Immunology. 2017.5 Langan SM, Thomas KS, Williams HC. What is meant by "flare" in atopic dermatitis? A systematic review and proposal. Arch Dermatol. 2006;142:1190-1196.6 Nutten S. Atopic dermatitis: global epidemiology and risk factors. Annals of Nutrition and Metabolism. 2015;66(suppl 1): 8-16.7 Yosipovitch G, Papoiu AD. What causes itch in atopic dermatitis? Current Allergy and Asthma Reports. 2008;8:306-311.8 Weidinger, S, Novak, N. Atopic dermatitis. The Lancet Volume 387. 2016;10023:1109-1122.

View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-and-incyte-announce-positive-top-line-results-from-the-north-american-breeze-ad5-phase-3-study-of-oral-selective-jak-inhibitor-baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis-300995759.html

SOURCE Eli Lilly and Company

Company Codes: NASDAQ-NMS:INCY, NYSE:LLY

Go here to see the original:
Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in...

Immunology

Innate Immune Activation Behind Asthma Attacks from Common Cold – University of Michigan Health System News

While rhinoviruses, the culprit behind the so-called common cold, are generally harmless, for kids with asthma, colds often trigger asthma attacks. In fact, colds are the number one cause of asthma exacerbation in children and adults. Michigan Medicine researchers Marc Hershenson, M.D., division director of pediatric pulmonology at C.S. Mott Childrens hospital and Mingyuan Han, Ph.D. a postdoctoral fellow and their team are investigating why this is.

In a new paper in the journal Mucosal Immunology, they describe how the inflammasome, part of the immune response that turns on inflammation and other processes to fight pathogens like bacteria and viruses and other harmful substances, is activated by rhinoviruses in a mouse model. This activation sensitizes the airway in both normal mice and allergic mice. This finding points to the inflammasome as a possible target for treatment of cold-induced asthma attacks.

Paper cited:Inflammasome activation is required for human rhinovirus-induced airway inflammation in naive and allergen-sensitized mice, Mucosal Immunology. DOI: 10.1038/s41385-019-0172-2

Follow this link:
Innate Immune Activation Behind Asthma Attacks from Common Cold - University of Michigan Health System News

Immunology

Global Flow Cytometry Market Size is Projected to Reach USD 6.4 Billion by 2025 from USD 4.0 Billion in 2019, Growing at a CAGR of 8.3% -…

DUBLIN--(BUSINESS WIRE)--The "Flow Cytometry Market by Technology (Cell-based, Bead-based), Product (Analyzer, Sorter, Reagents, Consumables, Software), End user (Academia, Research Labs, Hospitals, Clinical Laboratories, Pharma-Biotech Cos), Application - Global Forecasts to 2025" report has been added to ResearchAndMarkets.com's offering.

The key factors driving the growth of this market include technological advancements in flow cytometers, the increasing adoption of flow cytometry in research and clinical trials, growing focus on immunology and immuno-oncology research, increasing incorporation of AI platforms in flow cytometry workflows and advancements in flow cytometry software, high incidence and prevalence of target diseases, and the availability of novel products.

The bead-based technology segment is expected to grow at the fastest rate during the forecast period.

By technology, the flow cytometry market is classified into cell-based and bead-based. In 2019, the cell-based flow cytometry segment accounted for the largest share of the market. However, the bead-based flow cytometry segment is expected to grow at the highest CAGR during the forecast period. The growth of the bead-based flow cytometry segment can be attributed to the procedural advantages offered by this technology over other cell-based technology, such as the capacity to detect multiple analytes (also known as multiplexing), high reproducibility, stability, and speed.

The reagents and consumables segment is expected to grow at the highest CAGR during 2019-2025.

On the basis of product and service, the flow cytometry market is categorized into reagents and consumables, instruments, services, software, and accessories. The reagents and consumables segment is expected to witness the highest growth during the forecast period due to the development and commercialization of high-quality application-specific reagents and assays and continuous requirement of flow cytometry reagents by end-users (due to the increasing number of flow cytometry-based research activities).

The Asia Pacific to witness the highest growth during the forecast period (2019-2025)

North America is expected to hold the largest share of the global flow cytometry market in 2019 followed by Europe. However, the Asia Pacific is expected to grow at the fastest rate during the forecast period. The increasing participation of China, India, Japan, Australia, and South Korea in flow cytometry-based research; expansion of research infrastructure in the region; and public-private finding aimed towards boosting advance research practices are the key factors responsible for the growth of this market in the Asia Pacific.

Key Benefits of Buying the Report

This report focuses on various levels of analysis-industry trends, market shares of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the flow cytometry market, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

Key Topics Covered:

1 Introduction

1.1 Objectives of the Study

1.2 Market Definition

1.3 Study Scope

1.4 Currency Used for the Study

1.5 Stakeholders

2 Research Methodology

2.1 Research Data

2.2 Market Estimation Methodology

2.3 Data Triangulation Methodology

2.4 Research Assumptions

2.5 Research Limitations

3 Executive Summary

4 Premium Insights

4.1 Flow Cytometry: Market Overview

4.2 Flow Cytometry Products & Services Market, 2019 vs. 2025

4.3 Market, By Application, 2019 vs. 2025

4.4 Market, By End User, 2019 vs. 2025

4.5 Geographical Snapshot of the Market

5 Market Overview

5.1 Introduction

5.2 Market Dynamics

5.2.1 Drivers

5.2.2 Restraints

5.2.3 Opportunities

5.2.4 Challenges

5.3 Regulatory Challenges

5.4 US Reimbursement Scenario

6 Flow Cytometry Market, By Technology

6.1 Introduction

6.2 Cell-Based Flow Cytometry

6.3 Bead-Based Flow Cytometry

7 Flow Cytometry Market, By Product & Service

7.1 Introduction

7.2 Reagents & Consumables

7.3 Flow Cytometry Instruments

7.4 Services

7.5 Software

7.6 Accessories

8 Flow Cytometry Market, By Application

8.1 Introduction

8.2 Research Applications

8.3 Clinical Applications

8.4 Industrial Applications

9 Flow Cytometry Market, By End User

9.1 Introduction

9.2 Academic & Research Institutes

9.3 Hospitals & Clinical Testing Laboratories

9.4 Pharmaceutical & Biotechnology Companies

10 Flow Cytometry Market, By Region

10.1 Introduction

10.2 North America

10.3 Europe

10.4 Asia Pacific

10.5 Latin America

10.6 Middle East and Africa

11 Competitive Landscape

11.1 Introduction

11.2 Competitive Leadership Mapping

11.3 Competitive Leadership Mapping: Major Market Players (2018)

11.4 Competitive Leadership Mapping: Emerging Companies/SMEs/Start-Ups (2018)

11.5 Competitive Scenario (2016-2019)

11.6 Global Market Share Analysis, Top Three Market Players (2018)

12 Company Profiles

12.1 Becton, Dickinson and Company

12.2 Beckman Coulter

12.3 Thermo Fisher Scientific

12.4 Merck KGaA

12.5 Luminex Corporation

12.6 Agilent Technologies

12.7 Sony Biotechnology

12.8 Bio-Rad Laboratories

12.9 Miltenyi Biotec

12.10 Enzo Life Sciences, Inc.

12.11 Sysmex Partec

12.12 Biomrieux SA

12.13 Cytonome/St, LLC

12.14 Stratedigm, Inc.

12.15 Apogee Flow Systems

12.16 Cytek Biosciences, Inc.

12.17 Other Companies

12.17.1 Sartorius AG

12.17.2 Union Biometrica, Inc.

12.17.3 Nanocellect Biomedical, Inc.

12.17.4 On-Chip Biotechnologies Co., Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/8ln964

See the original post here:
Global Flow Cytometry Market Size is Projected to Reach USD 6.4 Billion by 2025 from USD 4.0 Billion in 2019, Growing at a CAGR of 8.3% -...

Immunology

Ulcerative Colitis Immunology Drugs Market 2019 Industry Outline, Global Executive Players, Interpretation and Benefit Growth to 2025 – Jewish Life…

The research study provided by UpMarketResearch on Global Ulcerative Colitis Immunology Drugs Industry offers strategic assessment of the Ulcerative Colitis Immunology Drugs market. The industry report focuses on the growth opportunities, which will help the market to expand operations in the existing markets.Next, in this report, you will find the competitive scenario of the major market players focusing on their sales revenue, customer demands, company profile, import/export scenario, business strategies that will help the emerging market segments in making major business decisions. The Global Ulcerative Colitis Immunology Drugs Market contains the ability to become one of the most lucrative industries as factors related to this market such as raw material affluence, financial stability, technological development, trading policies, and increasing demand are boosting the market growth. Therefore, the market is expected to see higher growth in the near future and greater CAGR during the forecast period from 2019 to 2026.

Request Exclusively Free Sample PDF Of This Report At https://www.upmarketresearch.com/home/requested_sample/21759

Major Players included in this report are as follows Janssen Biotech Inc.Bristol-Myers Squibb CompanyAbbVie Inc.UCBCaresAMGENCelltrion HealthcareBiogenGenentech USA Inc.ROCHEPfizer Inc.

Ulcerative Colitis Immunology Drugs Market can be segmented into Product Types as AdalimumabCertolizumab PegolTofacitinibEtanerceptGolimumabAbataceptInfliximabOthers

Ulcerative Colitis Immunology Drugs Market can be segmented into Applications as Rheumatoid ArthritisCrohns Disease(CD)Ankylosing Spondylitis(AS)Psoriasis(Ps)Ulcerative Colitis(UC)

Ulcerative Colitis Immunology Drugs Market: Regional analysis includes:Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)North America (United States, Mexico, and Canada.)South America (Brazil etc.)The Middle East and Africa (GCC Countries and Egypt.)

Get Full Access with Complete ToC by purchasing This Report At https://www.upmarketresearch.com/buy/ulcerative-colitis-immunology-drugs-market

The Ulcerative Colitis Immunology Drugs report regulates a complete analysis of the parent market including dependent and independent sectors. The report provides strategic recommendations with the senior analysts consultation that gives a clear perspective to clients as to which strategy will help them best to penetrate a market. Further, the report sheds light on the raw material sources, organizational structure, production processes, capacity utilization, value chain, pricing structure, technologies, equipment, product specifications distribution channel, and serving segments. It demonstrates graphical information with figures and pictures for elucidation.

For More Information on this report, Request Inquiry At https://www.upmarketresearch.com/home/enquiry_before_buying/21759

Key Highlights of This Report: The report covers Ulcerative Colitis Immunology Drugs applications, market dynamics, and the study of emerging and existing market segments. It portrays market overview, product classification, applications, and market volume forecast from 2019-2026. It provides analysis on the industry chain scenario, key market players, market volume, upstream raw material details, production cost, and marketing channels. The growth opportunities, limitations to the market growth are identified using the SWOT analysis It conducts the feasibility study, explores the industry barriers, data sources and provides key research findings The report delivers analysis on consumption volume, region-wise import/export analysis and forecast market from 2019-2026.

For Best Discount on purchasing this report, Visit https://www.upmarketresearch.com/home/request_for_discount/21759

About UpMarketResearch:Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected]Website https://www.upmarketresearch.comAddress 500 East E Street, Ontario, CA 91764, United States.

More:
Ulcerative Colitis Immunology Drugs Market 2019 Industry Outline, Global Executive Players, Interpretation and Benefit Growth to 2025 - Jewish Life...

Immunology

Deep Bench: Importance of flu shot for older adults and those with chronic conditions – WSAW

(WZAW) -- Flu season is far from over. In fact, most flu activity typically peaks between December and February, and activity can last as late as May.

While the CDC urges the public to get vaccinated by the end of October, experts agree that for those who havent gotten their flu shot by the holidays, it isnt too late to get a flu shot in the new year.

On Friday, Dr. Payel Gupta, an expert in immunology and respiratory health joined the Deep Bench, along with JoJo O'Neal, an asthma patient.

Dr. Gupta said for those who may have put it off, recent flu activity trends emphasize the need for late season flu vaccination, especially for groups who are at increased risk of flu and flu-related complications, like adults 50 years of age and older and people living with chronic medical conditions.

"It not only protects you, but protects those around you," Dr Gupta said. "We've already seen 6,660 deaths in the U.S. from the flu this year alone, so it's a big deal."

She added that bout 70 percent of adults 50 years of age and older have one or more chronic illnesses such as heart disease, asthma or other lung disease, diabetes and cancer. When combined with the flu, these chronic medical conditions can become worse and cause serious illness, hospitalizations and even death. Directly, flu can worsen symptoms of respiratory disorders such as asthma and chronic obstructive pulmonary disease and can lead to pneumonia. Multiple studies have found an increased risk of heart attack and stroke in the first few days following a flu infection.

Thats why the American Lung Association and Sanofi Pasteur launched the MyShot campaign, empowering people ages 50 and older to take ownership of their health and ask their doctor about flu shot options that might be right for them.

ONeal is a 55-year-old radio personality living with asthma. In 2017, she became sick with the flu, and it took her over 10 days to recover. During that time, she passed the virus on to her sister and niece. Now, she is making an annual flu shot a priority and wishes to educate others older adults to do the same.

"Prior to getting the flu, I had not taken the flu shot, and I don't want other people to go through what I went through," O'Neal said.

For more information, visit getmyshot.org

Original post:
Deep Bench: Importance of flu shot for older adults and those with chronic conditions - WSAW

Immunology

Richard Flavell Is Named a Distinguished Fellow by the American Association of Immunologists – Yale News

Richard A. Flavell, PhD, Sterling Professor of Immunobiology and aHoward Hughes Medical Institute investigator, has been named a Distinguished Fellowby the American Association of Immunologists (AAI), which calls this designation one of the highest honors that AAI bestows.

Flavell also is a fellow of the Royal Society and a member of the National Academy of Sciences, EMBO, and the National Academy of Medicine.His laboratoryuses transgenic and gene-targeted mice to study innate and adaptive immunity, T cell tolerance, and activation in immunity and autoimmunity, apoptosis, and regulation of T cell differentiation.

I am honored to be recognized in this way by the AAI, the premier immunology society, he says.

According to AAI, the honor recognizes "active, long-term members (25 or more years) who have demonstrated one or more of the following: excellence in research accomplishment in the field of immunology; exceptional leadership to the immunology community in academia, foundations, nonprofits, industry, or government at a national or international level; notable distinction as an educator."

Flavell is one of 20 scientists who have been designated Distinguished Fellowsfor 2020.

Submitted by Robert Forman on January 24, 2020

View original post here:
Richard Flavell Is Named a Distinguished Fellow by the American Association of Immunologists - Yale News

Immunology

William Petri – The Conversation UK

Profile Articles Activity

William A. Petri, Jr., M.D., Ph.D. studies immunology and molecular pathogenesis of enteric infections and their consequences. The scope of research includes molecular parasitology of Entamoeba, innate immune host defense against Clostridium difficile, and in Bangladesh acquired immunity to Cryptosporidium. We study infections in mouse models, in humans (including clinical trials) and at the lab bench.Petri leads the PROVIDE study of the Bill & Melinda Gates Foundation that is exploring in Bangladesh and India the pathogenesis of enteric environmental dysfunction (EED) and its association with oral poliovirus and rotavirus vaccine failures, malnutrition and neurocognitive developmental delay. Petri has received from Governor Terry McAuliffe both the Commonwealth of Virginia Outstanding Faculty Award (2014) and the Outstanding Scientist Award (2017). He has been recognized at UVa with the Kadner Award for Graduate Teaching, the All-University Teaching, and Inventor of the Year Awards. Petri has served as President of the American Society of Tropical Medicine and Hygiene and Editor of Infection and Immunity, and is currently Associate Editor for PLoS Pathogens, Clinical Infections Diseases and Trends in Molecular Medicine. He has received the Oswald Avery Award of the Infectious Diseases Society of America, the Burroughs Wellcome New Investigator and Scholar Awards in Molecular Parasitology, and the Lucille P. Markey Scholar Award in Biomedical Research. He has served continuously since 1993 on advisory committees for the NIH. Bill Petri received the MD and PhD (Microbiology) degrees from UVA, did medicine residency at Case Western and returned to UVA for infectious diseases fellowship. He spends 3 months of every year caring for patients on the general medicine and infectious diseases services and the remainder is focused on research on infectious diseases, especially the molecular pathogenesis of diarrheal infections in children living in poverty in Bangladesh and the immunology of C. difficile infection in a mouse model and in patients at UVA hospital.

Read more from the original source:
William Petri - The Conversation UK

Immunology

Post Doctoral Researcher, Biology job with MAYNOOTH UNIVERSITY | 194305 – Times Higher Education (THE)

Department : Biology

Closing Date : 05-Feb-2020

Applications are sought for position of Post-doctoral Researcher to conduct research within the Childhood Obesity Immunology research group of Dr. Andy Hogan. The successful candidate will join a programme of research investigating the impact of childhood obesity on the immune system.

This post is funded by the financial support of National Childrens Research Centre. Research in the research group aims to explore mechanisms of disease combining molecular, metabolic and cellular approaches utilizing well characterised patient cohorts.

More information on the research efforts of the Childhood Obesity Immunology group can be obtained from the following publications; Tobin et al, JCI insight 2017, Carolan et al, JI 2015, Carolan et al, JCEM 2013.

Post Doctoral Researcher Scale:37,874 - 40,221 per annum (3 Points)

Appointment will be made in accordance with the Department of Finance pay guidelines.

*New entrants to the public sector will be appointed on the first point of the above scale.

Closing Date:

23:30hrs (local Irish time) on Wednesday, 5th February 2020.

Applications must be submitted by the closing date and time specified. Any applications which are still in progress at the closing time on the specified closing date will be cancelled automatically by the system.

Late applications will not be accepted.

Read the original:
Post Doctoral Researcher, Biology job with MAYNOOTH UNIVERSITY | 194305 - Times Higher Education (THE)

Immunology

Feds fund innovative health research happening at Dal, NSHA and IWK – Dal News

Dalhousie University is home to four of the newest recipients of funding from the Government of Canada for their innovative health research.

The $1,159,527 in funding is provided by the Canadian Institutes of Health Research (CIHR) Project Grants, which help researchers gather the kind of information they need to make real improvements to clinical practice, health service delivery, and public health policy.

The Project Grant competition is one of CIHRs flagship funding programs. They are multi-year grants that are designed to support researchers at various stages in their careers as they conduct health research and knowledge translation projects that cover the full range of health research topic. Project grant recipients are leaders in their fields and their projects tackle pressing health issues that matter to Canadians, such as chronic pain management, mental health literacy intervention for Indigenous youth, and harnessing mast cell responses to viral infections.

In addition, four clinician scientists affiliated with the Nova Scotia Health Authority (NSHA) and the IWK Health Centre also received funding, bring the total in new health research funding to $3.2 million.

The researchers receiving funding include:

Paul Gratzer, Associate Professor, Department of Process Engineering and Applied Science, School of Biomedical EngineeringProject: Application of Advanced Wound Care Products and Techniques in the Northern Ontario First Nations Community

Noreen Kamal, Assistant Professor, Department of Industrial EngineeringProject: Atlantic Canada Together Enhancing Acute Stroke Treatment (ACTEAST): Improving Access and Efficiency of Treatment

Jean Marshall, Professor, Department of Microbiology & ImmunologyProject: Harnessing Mast Cell Responses to Viral Infections

Yifeng Wei, Assistant Professor, Department of PsychiatryProject: Developing, Evaluating, Disseminating and Sustaining a School-Based Mental Health Literacy Intervention for Indigenous Youth

Javeria Hashmi, Affiliated Scientist, Nova Scotia Health Authority and Assistant Professor, Department of Anesthesia, Pain Management and Perioperative MedicineProject: Strategy for Understanding How Expectations Interfere with Chronic Pain Management: A Multi-Modal Neuroimaging Study.

Rudolf Uher, Psychiatrist, Nova Scotia Health Authority and Professor, Department of PsychiatryProject: Sleep and Circadian Rhythm as Development Antecedents to Major Mood Disorders

Francesca Di Cara, Department of Pediatrics, IWK Health Centre and Assistant Professor, Departments of Pediatrics/Microbiology and Immunology Project: Defining the Peroxisome-Lipid Signaling Network in Innate Immunity

Souvik Mitra, Division of Neonatal-Perinatal Medicine, IWK Health Centre and Assistant Professor, Department of Pediatrics.Project: Relative Effectiveness and Safety of Pharmacotherapeutic Agents for Treatment of Patent Ductus Arteriosis (PDA) in Preterm Infants: A National Comparative Effectiveness Research (CER) Project.

Highlights of successfully funded projects:

Application of Advanced Wound Care Products and Techniques in the Northern Ontario First Nations Community

First Nations people living in Canada are among the highest risk population for diabetes and related complications. Community-based and culturally appropriate prevention strategies and monitoring of indications of diabetes among this high-risk population are essential to reducing health disparities.

With diabetes, minor abrasions and cuts on the feet can become chronic, infected wounds. Once the infection reaches the bone, amputation often becomes necessary. Canada currently spends $1.5 billion on direct costs for diabetic amputations, and in Ontarios North West Local Health Integration Network area alone, there were more than 100 amputations last year, which cost up to $43 million.

Paul Gratzer who has developed a new tissue engineered would care product called DermGEN, is working with Joanne Ogden, an award winning wound care nurse who has created a Wound Care Centre of Excellence in the Fort Frances area with a focus on limb preservation. DermGEN was created through research at Dalhousie and will be applied in a clinical study to assess the efficacy of this product in treating diabetic ulcers in the First Nations Communities of Northwest Ontario. DermGEN is unique in that it can be stored at room temperature, is easily transportable, and requires simple wound preparation and aftercare treatment which can be managed by patients at home.

"I am very excited to receive this funding as it enables my research to be used in helping a population who experience the highest rates in Canada of diabetic complications that lead to limb amputations, says Prof Gratzer. In partnership with the local First Nations communities, their Chiefs and Elders, and local wound care clinicians, we will bring advanced wound care technology directly to diabetic ulcer patients enabling them to heal faster and potentially eliminate the need for amputations.

Prof. Gratzers hope is that this research will significantly improve wound care in the First Nations communities at a lower cost.

Atlantic Canada Together Enhancing Acute Stroke Treatment (ACTEAST): Improving Access and Efficiency of Treatment

Stroke is a devastating disease, and the leading cause of severe physical disability. Ischemic stroke is the most common form of stroke; and is treatable with medical treatment and a new minimally invasive surgical procedure. These treatments can transform lives, but minutes matter for improving outcomes.

Dr. Noreen Kamals research is focused on increasing the proportion of ischemic stroke patients receiving treatment, and improving the efficiency of treatment. Her team will carry out this work across all of the Atlantic provinces, and employ an Improvement Collaborative intervention. This intervention uses the Model for Improvement adopted from Industrial Engineering, which employs alternatingface-to-face workshops and action periods to test and implement changes at local hospitals. The workshops involve sharing information with hospital teams and facilitation of cross-site learning.

It is anticipated that the potential benefit for patients experiencing ischemic stroke is profound. It is anticipated that 10-20% of ischemic stroke patients will have improved outcomes, which means that up to 550 more patients each year in Atlantic Canada can return to their homes with no or little disability, and use much less rehabilitation and long-term care services.

This funding means so much because ACTEAST is incredibly important to me for a number of reasons, says Dr. Kamal.The first reason is for the patients of course, who deserve the best possible outcomes that medical evidence has to offer. This brings me to my second reason, this is a cluster trial using a novel design to rigorously study the impact of an implementation, which will show its impact on being able to mobilize knowledge obtained from randomized clinical trial into practice. Finally, I have fallen in love with this region and its people; I look forward to working with the people from Atlantic Canada across four provinces and multiple health authorities to make it one of the best performing acute stroke systems in the world.

For more information about the CIHRs Project Grant program can be found on the CIHR website.

Visit link:
Feds fund innovative health research happening at Dal, NSHA and IWK - Dal News